Literature DB >> 6183389

Urinary excretion of alanine-aminopeptidase and N-acetyl-beta-D-glucosaminidase during sequential combination chemotherapy.

U Diener, E Knoll, D Ratge, B Langer, H Wisser.   

Abstract

The urinary excretion of alanine aminopeptidase (EC 3.4.11.2) and N-acetyl-beta-D-glucosaminidase (EC 3.2.1.30) was determined in 23 patients with testicular cancer during sequential combination chemotherapy with vinblastine/bleomycin and doxorubicin/cis-platinum. Increases in enzyme excretion were more often noticed during therapy with vinblastine/bleomycin than with doxorubicin/cis-platinum. Moreover, the rises during vinblastine/bleomycin therapy were more pronounced. The enzyme activities varied from the normal range up to the 14-fold of the upper limit of the normal range. With few exceptions, enzyme excretions returned to normal or slightly elevated values before the subsequent course. No renal insufficiency could be detected with the commonly used parameters of renal function such as serum creatinine concentrations and creatinine clearance values, which were determined at irregular intervals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183389     DOI: 10.1515/cclm.1982.20.9.615

Source DB:  PubMed          Journal:  J Clin Chem Clin Biochem        ISSN: 0340-076X


  5 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Stabilization of alanine aminopeptidase, gamma glutamyltranspeptidase, and N-acetyl-beta-D-glucosaminidase activity in normal urines.

Authors:  P W Mueller; M L MacNeil; K K Steinberg
Journal:  Arch Environ Contam Toxicol       Date:  1986-07       Impact factor: 2.804

Review 3.  Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions.

Authors:  Uwe Christians; Jost Klawitter; Jelena Klawitter; Nina Brunner; Volker Schmitz
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-02       Impact factor: 4.481

4.  Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.

Authors:  M P Goren; A A Forastiere; R K Wright; M E Horowitz; R K Dodge; B A Kamen; M J Viar; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Cumulative renal tubular damage associated with cisplatin nephrotoxicity.

Authors:  M P Goren; R K Wright; M E Horowitz
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.